Impact of an Embedded Palliative Care Clinic on Healthcare Utilization for Patients With a New Thoracic Malignancy.

embedded healthcare utilization lung cancer palliative care thoracic

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 15 12 2021
accepted: 07 02 2022
entrez: 17 3 2022
pubmed: 18 3 2022
medline: 18 3 2022
Statut: epublish

Résumé

Palliative care is beneficial for patients with advanced lung cancer, but the optimal model of palliative care delivery is unknown. We investigated healthcare utilization before and after embedding a palliative care physician within a thoracic medical oncology "onco-pall" clinic. This is a retrospective cross-sectional cohort study comparing healthcare outcomes in two cohorts: "pre-cohort" 12 months prior to and "post-cohort" 12-months after the onco-pall clinic start date. Patients were included if they had a new diagnosis of lung cancer and received care at The Ohio State University Thoracic Oncology Center, and resided in Franklin County or 6 adjacent counties. During the pre-cohort time period, access to palliative care was available at a stand-alone palliative care clinic. Palliative care intervention in both cohorts included symptom assessment and management, advance care planning, and goals of care discussion as appropriate. Outcomes evaluated included rates of emergency department (ED) visits, hospital admissions, 30-day readmissions, and intensive care unit (ICU) admissions. Estimates were calculated in rates per-person-years and with Poisson regression models. In total, 474 patients met criteria for analysis (214 patients included in the pre-cohort and 260 patients in the post-cohort). Among all patients, 52% were male and 48% were female with a median age of 65 years (range 31-92). Most patients had non-small cell lung cancer (NSCLC - 17% stage 1-2, 20% stage 3, 47% stage 4) and 16% had small cell lung cancer. The post-cohort was older [median age 66 years vs 63 years in the pre-cohort (p-value: < 0.01)]. The post-cohort had a 26% reduction in ED visits compared to the pre-cohort, controlling for age, race, marital status, sex, county, Charlson score at baseline, cancer type and stage (adjusted relative risk: aRR: 0.74, 95% CI: 0.58-0.94, p-value = 0.01). Although not statistically significant, there was a 29% decrease in ICU admissions (aRR: 0.71, 95% CI: 0.41-1.21, p-value = 0.21) and a 15% decrease in hospital admissions (aRR: 0.85, 95% CI: 0.70-1.03, p-value = 0.10). There was no difference in 30-day readmissions (aRR: 1.03, 95% CI: 0.73-1.45, p-value = 0.85). Embedding palliative care clinics within medical oncology clinics may decrease healthcare utilization for patients with thoracic malignancies. Further evaluation of this model is warranted.

Identifiants

pubmed: 35295997
doi: 10.3389/fonc.2022.835881
pmc: PMC8919515
doi:

Types de publication

Journal Article

Langues

eng

Pagination

835881

Informations de copyright

Copyright © 2022 Gast, Benedict, Grogan, Janse, Saphire, Kumar, Bertino, Agne and Presley.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Palliat Med Rep. 2021 May 17;2(1):137-145
pubmed: 34223513
J Oncol Pract. 2017 Sep;13(9):e729-e737
pubmed: 28562197
J Clin Oncol. 2015 May 1;33(13):1438-45
pubmed: 25800768
CA Cancer J Clin. 2018 Sep;68(5):356-376
pubmed: 30277572
J Pain Symptom Manage. 2015 Dec;50(6):758-67
pubmed: 26296261
Eur J Cancer. 2020 Jan;124:186-193
pubmed: 31812934
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
Lancet. 2014 May 17;383(9930):1721-30
pubmed: 24559581
Cancer. 2020 Jan 1;126(9):2013-2023
pubmed: 32049358
Oncologist. 2016 Sep;21(9):1149-55
pubmed: 27412394
J Oncol Pract. 2010 Nov;6(6):e17-20
pubmed: 21358945
J Oncol Pract. 2017 Feb;13(2):119-121
pubmed: 28972832
J Pain Symptom Manage. 2010 Jul;40(1):126-35
pubmed: 20619215
Lancet Oncol. 2018 Mar;19(3):394-404
pubmed: 29402701
J Clin Oncol. 2017 Mar 10;35(8):834-841
pubmed: 28029308
J Oncol Pract. 2017 Sep;13(9):e792-e799
pubmed: 28813191
J Palliat Med. 2018 Aug 1;:
pubmed: 30067150

Auteurs

Kelly C Gast (KC)

Division of Medical Oncology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH, United States.

Jason A Benedict (JA)

Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, United States.

Madison Grogan (M)

Division of Medical Oncology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH, United States.

Sarah Janse (S)

Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, United States.

Maureen Saphire (M)

Department of Pharmacy, The Ohio State University James Comprehensive Cancer Center, Columbus, OH, United States.

Pooja Kumar (P)

Department of Pharmacy, The Ohio State University James Comprehensive Cancer Center, Columbus, OH, United States.

Erin M Bertino (EM)

Division of Medical Oncology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH, United States.

Julia L Agne (JL)

Division of Palliative Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States.

Carolyn J Presley (CJ)

Division of Medical Oncology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH, United States.

Classifications MeSH